Form D · Pharmaceuticals
Acurx Pharmaceuticals, Inc.
Staten Island, NY · CIK 0001736243
Offering snapshot reported Apr 29, 2026 · SEC filing
- Reported sold
- $4.59M Offering amount: $4.59M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 15, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 29, 2026 | Initial | $4,587,473 | No comparison | 5 | SEC filing |
| Jun 27, 2025 | Initial | $3,978,664 | No comparison | 1 | SEC filing |
| May 20, 2025 | Initial | $0 | No comparison | 1 | SEC filing |
| Mar 21, 2025 | Initial | $3,376,350 | No comparison | 6 | SEC filing |
| Jan 17, 2025 | Initial | $2,404,259 | No comparison | 12 | SEC filing |
| Jan 17, 2020 | Initial | $455,000 | No comparison | 21 | SEC filing |
| Oct 30, 2019 | Amendment | $7,842,500 | $4,031,000vs Oct 30, 2018 | 202 | SEC filing |
| Oct 30, 2018 | Amendment | $3,811,500 | $940,000vs May 31, 2018 | 72 | SEC filing |
| May 31, 2018 | Amendment | $2,871,500 | $790,000vs Apr 3, 2018 | 61 | SEC filing |
| Apr 3, 2018 | Initial | $2,081,500 | No comparison | 47 | SEC filing |
Offering details
- Securities
- Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-582296
The Total Offering amount reflects the aggregate exercise price of the warrants.
Source: Form D, filed Apr 29, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Baehr | Director |
| Jack H. Dean | Director |
| Robert J. Deluccia | Director, Executive |
| Robert J. De Luccia | Director, Executive |
| James Donohue | Director |
| Michael Duffy | Director |
| Thomas Harrison | Director |
| Anthony Jadhon | Director |
| Katie Jadhon | Director |
| David P. Luci | Director, Executive |
| Mark Rathjen | Director |
| Carl Sailer | Director |
| Joseph Scodari | Director |
| Robert G. Shawah | Executive |
| John Terrana | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
259 Liberty Avenue
Staten Island, NY, 10305
Phone: 917-533-1469
Staten Island, NY, 10305
Phone: 917-533-1469